Sangamo Therapeutics (SGMO) Operating Leases (2019 - 2025)
Historic Operating Leases for Sangamo Therapeutics (SGMO) over the last 9 years, with Q3 2025 value amounting to $25.4 million.
- Sangamo Therapeutics' Operating Leases fell 830.6% to $25.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.4 million, marking a year-over-year decrease of 830.6%. This contributed to the annual value of $26.3 million for FY2024, which is 2166.79% down from last year.
- Latest data reveals that Sangamo Therapeutics reported Operating Leases of $25.4 million as of Q3 2025, which was down 830.6% from $23.5 million recorded in Q2 2025.
- Sangamo Therapeutics' Operating Leases' 5-year high stood at $44.1 million during Q4 2021, with a 5-year trough of $23.5 million in Q2 2025.
- Its 5-year average for Operating Leases is $34.8 million, with a median of $36.4 million in 2023.
- Per our database at Business Quant, Sangamo Therapeutics' Operating Leases surged by 1473.85% in 2021 and then tumbled by 2166.79% in 2024.
- Quarter analysis of 5 years shows Sangamo Therapeutics' Operating Leases stood at $44.1 million in 2021, then fell by 11.51% to $39.0 million in 2022, then fell by 14.03% to $33.5 million in 2023, then decreased by 21.67% to $26.3 million in 2024, then fell by 3.16% to $25.4 million in 2025.
- Its last three reported values are $25.4 million in Q3 2025, $23.5 million for Q2 2025, and $24.9 million during Q1 2025.